<DOC>
	<DOCNO>NCT00168701</DOCNO>
	<brief_summary>Determine efficacy , safety , tolerability BG00012 MS patient .</brief_summary>
	<brief_title>Efficacy Safety BG00012 MS</brief_title>
	<detailed_description>The study divide two part : Part 1 24-week , blind , placebo-controlled treatment phase follow Part 2 , 24-week blind , safety extension phase subject receive BG00012 .</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis , Relapsing-Remitting</mesh_term>
	<mesh_term>Dimethyl Fumarate</mesh_term>
	<criteria>1 . Must 18 55 year old , inclusive , time informed consent . 2 . Must confirm diagnosis relapsingremitting MS accord McDonald criterion # 14 ( McDonald et al , 2001 ; Appendix 2 ) . 3 . Must baseline EDSS 0.0 5.0 , inclusive . 5 . Must experience least one relapse within 12 month prior randomization , prior cranial MRI demonstrate lesion ( ) consistent MS OR show evidence Gdenhancing lesion brain MRI perform within 6 week . 6 . Male female subject must willing take appropriate measure prevent pregnancy . 1 . Primary progressive , secondary progressive , progressive relapsing MS ( define Lublin Reingold , 1996 [ Appendix 3 ] ) . 2 . History malignancy . 3 . History severe allergic anaphylactic reaction know drug hypersensitivity . 4 . History abnormal laboratory result indicative significant cardiac , endocrinologic , hematologic , hepatic , immunologic , metabolic , urologic , pulmonary , gastrointestinal , dermatologic , psychiatric , renal , neurologic ( MS ) , and/or major disease . 5 . History human immunodeficiency virus ( HIV ) . 6 . History drug alcohol abuse ( define Investigator ) within 2 year prior randomization . 7 . An MS relapse occur within 50 day prior randomization AND/OR subject stabilize previous relapse prior randomization . 8 . Body weight &gt; 100 kg . 9 . Positive hepatitis C antibody and/or positive hepatitis B surface antigen ( HBsAg ) screening . 10 . Any following abnormal blood test screen . 11 . Any previous treatment FUMADERMÂ® , FAG201 , BG00012 . 12 . A medication history precludes entry study . 13 . Female subject currently pregnant breastfeed .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>November 2007</verification_date>
	<keyword>Multiple Sclerosis</keyword>
	<keyword>MRI</keyword>
</DOC>